Table 1 Patient characteristics

Age

Median (range)

67 (25–84)

69 (40–85)

0.16

> 65

71

62.8

96

69.6

0.261

Sex

Male

78

69

88

63.8

0.381

Female

35

31

50

36.2

0.381

ECOG PS

0

85

75.2

88

63.8

0.051

1

25

22.1

43

31.2

0.109

> 2

3

2.7

7

5.1

0.261

Previous gastrectomy

Yes

35

31

41

29.7

0.828

No

78

69

97

70.3

0.828

6

5.3

8

5.8

0.867

Time to progressive disease on first-line therapy

< 6 months

75

66.4

78

56.5

0.112

> 6 months

38

33.6

60

43.5

0.112

HER2

Positive

13

11.5

23

16.7

0.246

Negative

99

87.6

112

81.1

0.165

Unknown

1

0.9

3

2.2

0.39

Histology

Diffuse

69

61.1

82

59.4

0.792

Intestinal

43

38.1

52

37.7

0.952

Mix, Missing

1

0.9

4

2.9

0.254

Number of metastatic sites

0–1

60

54

62

44.9

0.198

2

33

28.3

48

36.2

0.347

> 3

20

17.7

28

18.9

0.604

Metastatic site

Liver

32

28.3

46

33.3

0.393

Lung

18

15.9

19

13.8

0.631

Lymph node

54

47.8

74

53.6

0.358

Peritoneum

70

61.9

80

58

0.523

Others

13

11.5

26

18.8

0.11

Prior therapy

Fluoropyrimidine

113

100

138

100

–

Platinum

107

94.7

130

94.2

0.867

Trastuzumab

10

8.8

21

15.2

0.127

Ascites

None

59

52.2

75

54.3

0.736

Small

22

19.5

20

14.5

0.293

Moderate

14

12.4

15

10.9

0.708

Massive

18

15.9

28

20.3

0.374

None/small

81

71.7

95

68.8

0.625

Moderate/massive

32

28.3

43

31.2

0.625